The MedicalXpress report on a new global review reveals stark differences in how countries regulate polygenic embryo testing during IVF, noting over 10 million IVF births worldwide. However, it stops short of examining the deeper consequences: how this regulatory patchwork enables a de facto genetic marketplace that favors the wealthy and risks normalizing a new form of eugenics. The primary review itself is a qualitative policy analysis covering regulations in approximately 35 countries; it is observational in design with no RCT equivalent possible for policy mapping, and no conflicts of interest were declared.

Synthesizing this with peer-reviewed sources exposes what original coverage missed. A 2023 scoping review in the Journal of Medical Ethics (qualitative analysis of 42 jurisdictions, sample of policy documents, no COI reported) shows the United States has virtually no federal statutes specifically addressing polygenic risk score (PRS) embryo selection, relying instead on voluntary ASRM guidelines that lack enforcement. In contrast, the UK and several EU nations restrict such testing to severe monogenic conditions under the HFEA framework. This gap creates 'regulation shopping' where high-net-worth individuals can access clinics in permissive jurisdictions.

A related 2022 large-scale GWAS meta-analysis in Nature Genetics (observational study, n > 1.2 million mostly European-ancestry participants, declared conflicts with commercial genomics firms) found PRS for complex traits like educational attainment explain only 4-12% of variance in out-of-sample predictions. When applied to embryos, predictive accuracy drops further due to limited heritability capture and ancestry bias. The original source failed to connect these weak validity metrics to ethical hazards: companies are already marketing tests for intelligence, height, and disease risk, despite the science remaining preliminary and prone to false positives.

Patterns from related events reinforce the concern. The 2018 He Jiankui CRISPR-edited babies case illustrated how weak international oversight allows rogue actors to exploit regulatory voids, leading to global condemnation but no binding treaty. Similarly, the rapid commercialization of direct-to-consumer genetic testing outpaced oversight, resulting in documented harms from misleading health claims (observational FDA adverse event reports, n=several thousand). Without WHO-led or UN-backed standards, polygenic embryo testing threatens to widen existing inequalities: only affluent families can afford the $15,000–$30,000 add-on to IVF cycles, potentially creating genetically 'optimized' cohorts with compounded advantages in health, cognition, and longevity.

The review also overlooked commercial pressures accelerating adoption ahead of robust evidence. No large randomized controlled trials exist to assess clinical utility or long-term outcomes of PRS embryo selection; all current data derive from retrospective observational cohorts with significant selection bias and industry funding in several key studies. This vacuum invites exploitation, demanding urgent international harmonization to prevent reproductive technologies from becoming tools of stratified genetic advantage.